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GRP75/Mortalin as peripherally accessible protein
biomarkers for spinal muscular atrophy
Chantal A Mutsaers1,2, Douglas J Lamont3, Gillian Hunter1,2, Thomas M Wishart1,4† and Thomas H Gillingwater1,2*†Abstract
Background: Spinal muscular atrophy (SMA) is a neuromuscular disease resulting from mutations in the survival
motor neuron 1 (SMN1) gene. Recent breakthroughs in preclinical research have highlighted several potential novel
therapies for SMA, increasing the need for robust and sensitive clinical trial platforms for evaluating their
effectiveness in human patient cohorts. Given that most clinical trials for SMA are likely to involve young children,
there is a need for validated molecular biomarkers to assist with monitoring disease progression and establishing
the effectiveness of therapies being tested. Proteomics technologies have recently been highlighted as a potentially
powerful tool for such biomarker discovery.
Methods: We utilized label-free proteomics to identify individual proteins in pathologically-affected skeletal muscle
from SMA mice that report directly on disease status. Quantitative fluorescent western blotting was then used to
assess whether protein biomarkers were robustly changed in muscle, skin and blood from another mouse model of
SMA, as well as in a small cohort of human SMA patient muscle biopsies.
Results: By comparing the protein composition of skeletal muscle in SMA mice at a pre-symptomatic time-point
with the muscle proteome at a late-symptomatic time-point we identified increased expression of both Calreticulin
and GRP75/Mortalin as robust indicators of disease progression in SMA mice. We report that these protein biomarkers
were consistently modified in different mouse models of SMA, as well as across multiple skeletal muscles, and were
also measurable in skin biopsies. Furthermore, Calreticulin and GRP75/Mortalin were measurable in muscle biopsy
samples from human SMA patients.
Conclusions: We conclude that label-free proteomics technology provides a powerful platform for biomarker
identification in SMA, revealing Calreticulin and GRP75/Mortalin as peripherally accessible protein biomarkers
capable of reporting on disease progression in samples of muscle and skin.Background
The autosomal recessive disease spinal muscular atrophy
(SMA) is caused by deficient expression of full-length
survival motor neuron (SMN) protein resulting from
disruption to the survival motor neuron 1 (SMN1) gene
[1-3]. Although SMN is ubiquitously expressed, loss of
this protein has dramatic effects on the neuromuscular
system, including degeneration of lower motor neurons* Correspondence: t.gillingwater@ed.ac.uk
†Equal contributors
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reproduction in any medium, provided the orin the ventral horn of the spinal cord, disruption of nerve-
muscle connectivity at the neuromuscular junction, and
pathological changes in skeletal muscle [4-9]. Disease pro-
gression, as well as symptom severity, can vary significantly
between individual patients with SMA, largely dependent
upon the copy number of the near-identical SMN2 gene
[3,9]. A higher copy number of SMN2 correlates with a
milder phenotype. Similarly, disease-modifying genes are
known to exist that can influence the severity of a patient’s
condition [10].
This detailed understanding of SMA genetics has
facilitated exciting breakthroughs in pre-clinical research
over the past few years, with several approaches indicating
significant potential benefits in animal models of theal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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approaches to restore SMN1 expression have yielded
impressive amelioration in neuromuscular dysfunction
and large increases in the lifespan of mice with SMA
[11-14]. Other approaches aimed at increasing the amount
of SMN protein produced by the SMN2 gene by promoter
activation or reduction of alternative splicing of SMN2
exon 7 have also shown therapeutic benefit in animal
models [15-17]. As a result, there is a growing desire to
undertake clinical trials in human patient cohorts in order
to evaluate the potential benefits of these therapeutic
approaches. However, performing clinical trials in cohorts
of young patients (and in the case of severe forms of
SMA, neonatal patients) brings with it a range of technical
problems [18].
In order to improve the reliability and effectiveness of
SMA clinical trials, robust biomarkers are required. Firstly,
biomarkers are needed to allow accurate monitoring of
disease activity and to predict disease progression in
human patients [19]. Secondly, biomarkers are required to
provide more accurate measures of the responses of indi-
vidual patients and groups of patients to a new treatment
or therapeutic approach [20]. Several different approaches
have previously been employed in an attempt to identify
biomarkers for SMA in both mouse models and patient
cohorts, incorporating a range of physical, functional and
molecular readouts [19,21-23]. However, robust biomarkers
for SMA have yet to be identified.
Proteomics technologies have recently been highlighted
as a potentially powerful tool for biomarker discovery [20].
In this study, we have utilized a state-of-the-art, label-free
proteomics approach to identify individual proteins in the
neuromuscular system of SMA mice that report directly
on disease status. By comparing the protein composition
of skeletal muscle in SMA mice at a pre-symptomatic
time-point with the muscle proteome at a late-symptom-
atic time-point we identified increased expression of both
Calreticulin and GRP75/Mortalin as robust indicators
of disease progression. We report that these protein
biomarkers were similarly modified across two different
mouse models of SMA, across multiple skeletal muscles,
and also in skin biopsies. Furthermore, initial investigation
of Calreticulin and GRP75/Mortalin levels in muscle biopsy
samples suggested that these proteins are detectable and
measurable by western blot in tissue from human SMA
patients.
Methods
Mice
Two SMA mouse models were used (both on a congenic
FVB background). The ‘severe’ SMA mouse model [24]
(Smn−/−;SMN2tg/tg) was originally obtained from the
Jackson Laboratory (Bar Harbor, Maine, USA) and had a
mean survival of 5/6 days in our hands. The ‘Taiwanese’SMA mouse model (Smn−/−;SMN2tg/0) [25] was also
obtained from Jackson Laboratories and was maintained
following the breeding strategy devised by Riessland and
colleagues [26], giving a mean survival of 10/11 days.
Litters produced from both ‘severe’ SMA and ‘Taiwanese’
SMA mice were retrospectively genotyped using standard
PCR protocols (JAX® Mice Resources; the Jackson Labora-
tory (Bar Harbor, Maine, USA)), as previously described
[5,26]. All animal procedures and breeding were performed
in accordance with Home Office guidelines in the UK.
Human muscle samples
Quadriceps femoris biopsy samples were obtained, through
EuroBioBank [27], from two different biobanks in Italy;
Fondazione IRCCS Istituto Neurologico ‘C Besta’ in Milan
and Fondazione Ospediale Maggiore Polclinico Mangiagalli
en Regina Elena, IRCCS in Milan. All required ethical
approvals to acquire and distribute human patient tissue
samples were obtained by the host biobanks. Tissue was
shipped to Edinburgh in an anonymous fashion, with no
identifying details provided apart from the age, gender and
genetic status of the patients. Biopsies were obtained from
three type II/III SMA patients (aged between 3 and
25 years), with a homozygous deletion of the SMN1 gene
confirming a genetic diagnosis of SMA. Three age-matched
control samples were also obtained, genetically confirmed
to have no mutations in the SMN1 gene.
Mouse sample preparation
‘Severe’ SMA mice (Smn−/−;SMN2+/+) and wild-type
(Smn+/+;SMN2+/+) littermates at postnatal day 1 (P1) and
P5 were sacrificed by chilling on ice and decapitation.
Levator auris longus (LAL; from the back of the neck)
muscles were dissected in oxygenated mammalian physio-
logical saline, as previously described [28]. LAL muscles
were separated into rostral and caudal bands and quickly
frozen on dry ice. The rostral band of LAL from each
mouse was stored at −80°C until sufficient tissue was
collected for proteomics analysis.
‘Taiwanese’ SMA mice and littermate controls were
sacrificed at P1, P5, P7 and P9 before the gastrocnemius
muscle was dissected from each hind limb. At the same
time, a sample of skin from the belly was taken and a
few drops of blood were collected. All tissue was quickly
frozen on dry ice and stored in −80°C freezers for further
analysis.
Label-free proteomics
Protein was extracted in MEBC buffer (50 mM TRIS,
100 mM NaCl, 5 mM NaEDTA, 5 mM NaEGTA, 40 mM
β-glycerophosphate, 100 mM NaF, 100 mM sodium
orthovanadate, 0.25% NP-40, 1 Roche ‘complete’ protease
inhibitor tablet, pH 7.4). Protein concentration was deter-
mined by bicinchoninic acid assay (BCA; Thermo Scientific
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instructions on solubilised muscle (P1 wild-type and SMA
rostral and P5 wild-type and SMA rostral). Then 10 μg
aliquots of each muscle type were reduced with 10 mM
dithiothreitol and alkylated with 50 mM iodoacetamide
prior to digestion with trypsin (sequencing grade; Roche,
Indianapolis, IN, USA) overnight at 30°C. Technical repli-
cates (3 × 2.5 μg) of each digested muscle type were injected
onto a nano-scale liquid chromatographic tandem mass
spectrometry (nLC-MS/MS) system (Ultimate 3000 (Dio-
nex (Thermo Fisher), Hemel Hempstead, UK) coupled to a
LTQ Orbitrap XL (Thermo Scientific, Hemel Hempstead,
UK). The peptides from each digest were separated over a
65 minute linear gradient from 5 to 35% acetonitrile in
0.1% formic acid. The LTQ Orbitrap XL was configured
with a TOP 5 methodology comprising a 60 K resolution
FT-MS full scan followed by IT-MS/MS scans for the 5
most intense peptide ions. The raw data were then
imported into Progenesis LCMS for label free differential
analysis and subsequent identification and quantification
of relative ion abundance ratios, both up-regulated and
down-regulated. Following alignment of MS data, principal
component analysis and preliminary filtering (power >80%,
P > 0.05), data were exported from Progenesis as a single
mgf file per time-point. These files were then used to
identify individual peptide sequences using the Swiss-Prot
database via Mascot Daemon (v2.4.0) due to the large file
size. As an indication of identification certainty, the false
discovery rate for peptide matches above identity
threshold was 9.39% for P1 and 3.34% for P5. Protein
abundance data per experimental run/sample as an output
from the Progenesis software can be found in Additional
file 1 and abundance of individual peptides can be found
in Additional file 2. Statistical P-values presented in Tables 1
and 2 and Additional file 1 were automatically generated
using Progenesis software through a one-way Anova on
the ArcSinh transform of the normalised data.
These data from Mascot were then re-imported into
Progenesis for subsequent conflict resolution and protein
expression comparison. Stringent selection criteria were
used before a protein was included in our analyses;
identification of at least two peptides was needed and a
P-value <0.05 [29,30]. To be identified as a protein with
changed expression levels in SMA tissue, the protein
had to be up- or down-regulated by >20% compared to
wild-type controls. The mass spectrometry proteomics
data have been deposited in the ProteomeXchange Consor-
tium [31] via the PRIDE partner repository with the dataset
identifier PXD000488 and DOI10.6019/PXD000488.
Quantitative fluorescent western blotting
Protein was extracted from ‘Taiwanese’ SMA mouse
muscle, skin and blood samples and from human muscle bi-
opsies. Protein levels were quantified by BCA. Quantitativewestern blots were performed as described previously
[30,32]. Briefly, the membranes were put in 2% Ponceau
S for 10 minutes and then washed briefly in ddH2O
until the bands were clearly visible and the background
stain low. Then the membranes were blocked in buffer
for 30 minutes before incubating in primary antibodies
against Calreticulin (1:1,000; Lifespan Biosciences, Seattle,
WA, USA), GRP75 (1:2,500; Lifespan Biosciences) or TCP1
beta (1:1,000; Abcam, Cambridge, UK). Odyssey secondary
antibodies were added according to the manufacturer's
instructions (Goat anti rabbit IRDye 680 or 800, Goat
anti mouse IRDye 680 or 800 and Donkey anti Goat IRDye
800 dependent on required combinations; LI-COR Bio-
sciences, Cambridge, UK). Blots were imaged using an
Odyssey Infrared Imaging System (LI-COR Biosciences,
Cambridge, UK) at 169 μm resolution. Where possible,
each sample was independently run and measured twice
to minimise user variability.
Statistical analysis
All data were collected into Microsoft Excel spreadsheets
and then analysed using GraphPad Prism software. For all
statistical analyses P < 0.05 was considered to be significant.
Individual statistical tests used are detailed in the results
section or figure legends.
Results
Label-free proteomics analysis reveals a list of 23 putative
biomarkers of disease status in skeletal muscle from
‘severe’ SMA mice
In order to identify potential new protein biomarkers
capable of reporting directly on the progress of disease in
SMA, we utilized unbiased, label-free proteomics tech-
nologies to compare the proteome of a pathologically
affected tissue in SMA (skeletal muscle) [7] at early- and
late-symptomatic stages of the disease. Given the difficulty
in obtaining human muscle samples for such an experi-
ment, we performed these initial proteomic screens in the
LAL muscle of an established mouse model of SMA (the
‘severe’ SMA mouse; Smn−/−;SMN2+/+;) [24]. The mouse
LAL muscle is composed of two distinct muscle bands
that are differentially affected in SMA mice: a caudal band
that undergoes severe neuromuscular denervation [5,33]
and a rostral band that has minimal denervation but
intrinsic muscular pathology [7]. In order to obtain a
pathologically homogeneous tissue sample for proteomics
analysis, we chose to selectively examine the larger rostral
band of the muscle.
The rostral band of LAL muscle was dissected from
‘severe’ SMA mice and littermate controls (Smn+/+;
SMN2+/+) at P1 (pre/early-symptomatic) and P5 (n = 9
mice per genotype, per time-point) and proteins were
extracted for mass-spectrometry analysis. The raw data
from P1 animals was previously analysed using the IPI
Table 1 Proteins unchanged at P1 but increased >50% or 20 to 50% at P5 in the rostral band of LAL muscle from SMA
mice compared with littermate controls
Gene name Protein name Accession
number
Peptides
at P5
Ratio
KO/control P1
Ratio
KO/control at P5
Score
at P5
Anova
(P-value) at P5
G6pI Glucose-6-phosphate isomerase G6PI_MOUSE 6 1.03 1.98 245.68 6.92E-06
Grp75 Stress-70 protein GRP75_MOUSE 3 1.02 1.82 170.83 5.59E-04
Tbb5 Tubulin beta-5 chain TBB5_MOUSE 2 1.02 1.80 639.05 3.69E-05
Plec1 Plectin-1 PLEC1_MOUSE 21 1.18 1.63 879.72 4.67E-06
Thil Acetyl-CoA acetyltransferase THIL_MOUSE 7 1.09 1.59 448.39 2.95E-04
Calr Calreticulin CALR_MOUSE 3 1.12 1.51 83.76 2.08E-03
Aatm Aspartate aminotransferase AATM_MOUSE 7 1.17 1.50 443.54 1.50E-04
Thim 3-Ketoacyl-CoA thiolase THIM_MOUSE 12 1.02 1.41 473.14 1.16E-03
Anxa2 Annexin A2 ANXA2_MOUSE 10 1.04 1.33 729.11 1.28E-03
Pura1 Adenylosuccinate synthetase isozyme 1 PURA1_MOUSE 5 1.09 1.30 247.24 1.19E-03
S10ab Protein S100-A11 S10AB_MOUSE 2 1.01 1.25 166.21 2.78E-02
Hbb2 Hemoglobin subunit beta-2 HBB2_MOUSE 6 1.01 1.23 702.27 1.51E-03
Lmna Lamin-A/C LMNA_MOUSE 7 1.16 1.21 567.31 2.19E-04
Vime Vimentin VIME_MOUSE 12 1.17 1.21 776.2 3.50E-04
KO, knockout.
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study, to allow direct comparison with the P5 data, the P1
raw data were re-analysed in parallel with the P5 data as
detailed below.
The raw mass-spectrometry data from both P1 and P5
comparisons were uploaded to Progenesis label-free soft-
ware for further analyses. From each sample three replicate
runs were performed. One control replicate was chosen
as a reference dataset, based on a clear and representative
feature pattern with minimum distortion. All other runs
were then aligned to this reference dataset using the
Progenesis software. Alignment was performed to correct
for the variable elution of peptides during chromatographic
separation. Although Progenesis software automatically
aligns data from each experimental run, vectors were alsoTable 2 Proteins unchanged at P1 but decreased >50% or 20
mice compared with littermate controls
Gene name Protein name Accession
number
Peptide
t P5
Rrbp1 Ribosome-binding protein 1 RRBP1_MOUSE 3
Tpm1 Tropomyosin alpha-1 chain TPM1_MOUSE 6
Actn2 Alpha-actinin-2 ACTN2_MOUSE 15
Tcpb T-complex protein 1 subunit beta TCPB_MOUSE 3
Postn Periostin POSTN_MOUSE 3
Hs90a Heat shock protein HSP 90-alpha HS90A_MOUSE 3
Hs90b Heat shock protein HSP 90-beta HS90B_MOUSE 8
Rtn4 Reticulon-4 RTN4_MOUSE 5
Nb5r3 NADH-cytochrome b5 reductase 3 NB5R3_MOUSE 3
KO, knockout.added manually to align peptide ions where needed. After
aligning data from each of the runs, data filtering was
performed. All ions that were identified with an early
(less than 6 minutes) or late retention time (more than
72 minutes) were excluded. The runs were then grouped
according to the genotype of the mouse (for example,
into pooled control and SMA datasets) and an ANOVA
statistical test was performed to determine whether the
means of the two groups were equal. At this stage further
stringent filtering was performed and all 1+ charged ions
were excluded as unlikely to represent peptides.
Once the list of candidate peptide ions to identify was
created, their MS/MS data were exported to the Swiss-Prot
protein database to allow comparison to known peptides,
and subsequently proteins. The output of this Swiss-Protto 50% at P5 in the rostral band of LAL muscle from SMA
s a Ratio KO/control
at P1
Ratio KO/control
at P5
Score
at P5
Anova (P-value)
at P5
0.89 0.15 60.23 1.97E-05
0.92 0.25 652.67 6.87E-06
0.89 0.61 1413.57 1.82E-04
0.89 0.66 162.09 2.07E-03
0.99 0.70 142.66 7.55E-04
0.99 0.70 326.05 7.71E-04
0.90 0.70 600.51 6.45E-05
0.86 0.79 123.82 1.69E-02
0.95 0.79 65.43 3.90E-05
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order to allow further filtering by excluding peptides that
were not associated with more than one protein (conflict
resolving). Also, peptides that were improperly cleaved by
trypsin were excluded (for example, any peptide that had a
lysine or arginine mid-sequence, or any peptides not
ending with a lysine or arginine). This led to the identifica-
tion of 540 proteins in the P5 dataset (Figure 1A, left col-
umn). A filtering protocol was then applied for subsequent
stringent positive identification of proteins, with only those
proteins identified by two or more unique peptides taken
forward for further analysis. Proteins that were either
up- or down-regulated >20% in SMA muscle compared to
controls were considered to have an altered expression
profile (Figure 1A, middle column).
To be considered as a putative biomarker, we wanted to
identify proteins whose expression levels were unchanged
in SMA muscle at P1 (pre/early-symptomatic), but wereFigure 1 Identification of putative protein biomarkers for SMA in ske
process of filtering undertaken on the raw proteomics data in order to gen
at P5, but unchanged at P1. The left column shows all proteins identified b
total) in control and SMA (knockout (KO)) mouse LAL muscle at P5, with th
(KO/Control). The red bars indicate the 20% cutoff threshold for being up-r
middle column shows the proteins remaining in the P5 dataset following f
and were identified by at least two peptides (n = 245 proteins in total)). Th
changed in SMA mouse skeletal muscle at P5, but that were unchanged in
showing all 14 proteins that were unchanged at P1 in ‘severe’ SMA mouse
levels >20% at P5. (C) Graph showing all nine proteins that were unchange
controls, but had decreased levels >20% at P5. Dashed lines in B and C indsignificantly changed at P5 (late-symptomatic). We there-
fore took the list of all proteins with modified expression
in SMA mice at P5 compared to controls, and searched for
expression data for the same proteins in the P1 comparison
dataset. Any proteins found to have altered expression
at both P5 and P1 were considered to be unsuitable as a
biomarker and were therefore removed from the candidate
list (Figure 1A, right column). This filtering of data resulted
in the identification of 14 candidate biomarker proteins
that were up-regulated in ‘severe’ SMA mouse muscle at
P5 but not at P1 (Table 1, Figure 1B) and 9 proteins that
were down-regulated in ‘severe’ SMA mouse muscle at P5
but not at P1 (Table 2, Figure 1C).
Validation of putative protein biomarkers in the
‘Taiwanese’ mouse model of SMA
In order to validate the list of candidate biomarkers gener-
ated by our proteomics analysis of skeletal muscle fromletal muscle from ‘severe’ SMA mice. (A) Scatter plot showing the
erate a final list of 23 proteins modified in SMA mouse skeletal muscle
y the Progenesis label-free proteomics software (n = 540 proteins in
e relative expression levels between samples represented as a ratio
egulated or down-regulated in SMA mice compared to controls. The
iltering (for example, that were either up- or down-regulated by >20%
e right column shows those proteins that were identified as being
comparable muscle samples at P1 (n = 23 proteins in total). (B) Graph
LAL muscle compared to littermate controls, but had increased
d at P1 in ‘severe’ SMA mouse LAL muscle compared to littermate
icate 20% change cut-off thresholds.
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similar changes in protein levels could be detected in a
different skeletal muscle from a genetically unique mouse
model of SMA using quantitative fluorescent western
blotting. We chose three proteins to validate, based on the
magnitude of their expression change and the availability
of suitable antibodies for western blotting: Stress-protein
70 (GRP75/Mortalin) and Calreticulin were 1.8- and
1.5-fold up-regulated, respectively, in our proteomic data-
set whereas T-complex protein 1 subunit beta (TCP1)
was down-regulated by 1.5-fold. We measured levels of
these three proteins in the gastrocnemius muscle (from
the hind limb) of ‘Taiwanese’ SMA mice and littermate
controls [7,26].
Levels of TCP1, GRP75/Mortalin and Calreticulin
were measured in the gastrocnemius muscle of ‘Taiwanese’
SMA mice and littermate controls at a mid/late-symptom-
atic time-point (P9; Figure 2A). Levels of TCP1 were
unchanged in the SMA mice compared to controls
(Figure 2B), thereby failing to validate the original proteo-
mics data in a different model of SMA. However, in
contrast, levels of both GRP75/Mortalin and Calreticulin
were significantly increased in the ‘Taiwanese’ SMA
mouse muscle, showing that the changes in these proteins
were conserved between ‘severe’ and ‘Taiwanese’ SMA mice,
as well as between the LAL and gastrocnemius muscles
(Figure 2B,C).Figure 2 Validation of Calreticulin and GRP75/Mortalin as potential p
SMA mouse model. (A) Representative fluorescent western blots on gastr
littermate controls at P9 (mid/late-symptomatic) showing levels of TCPB, G
charts (mean ± standard error of the mean) showing expression levels of TC
mice (KO) at P9 (N = 3 mice per genotype). TCPB levels showed no differen
significant; P > 0.05, unpaired, two-tailed t-test) (B). GRP75 levels were signi
(**P < 0.01, unpaired, two-tailed t-test) (C). Calreticulin levels were also sign
(***P < 0.001, unpaired, two-tailed t-test) (D).Preliminary investigation of a small patient cohort
suggests that levels of GRP75/Mortalin and Calreticulin
are increased in human SMA patient muscle biopsies
Next, we wanted to establish whether the increased levels
of GRP75/Mortalin and Calreticulin, observed to correlate
with disease progression in SMA mouse models, were also
measurable in skeletal muscle from human SMA patients.
Therefore, we examined levels of GRP75/Mortalin and
Calreticulin using quantitative fluorescent western blot-
ting on human muscle biopsy samples obtained through
EuroBioBank (see Methods). We obtained biopsies from
the quadratus femoris from three type II/III SMA patients
(aged between 3 and 25 years). All three patients had a
genetic diagnosis of SMA confirmed by a homozygous
deletion of the SMN1 gene. Three roughly age-matched
control samples were also obtained, genetically confirmed
to have no mutations in the SMN1 gene.
Both GRP75/Mortalin and Calreticulin could be readily
identified and levels measured using quantitative fluores-
cent western blotting. Both GRP75/Mortalin and Calreti-
culin showed a trend towards increased levels in the small
cohort of SMA patients compared to controls (Figure 3).
GRP75/Mortalin levels increased on average by 50%
compared to controls, although the considerable variability
between individuals and low sample size meant that this
difference did not reach statistical significance (Figure 3B).
Calreticulin levels were significantly increased in the SMArotein biomarkers in a different muscle from a genetically distinct
ocnemius muscle from ‘Taiwanese’ SMA mice (knockout (KO)) and
RP75/Mortalin, Calreticulin and Ponceau (loading control). (B-D) Bar
PB, GRP75/Mortalin and Calreticulin in control and ‘Taiwanese’ SMA
ce in expression levels in SMA mice compared with controls (ns, not
ficantly increased in ‘Taiwanese’ SMA mice compared with controls
ificantly increased in Taiwanese-SMA mice compared with controls
Figure 3 GRP75/Mortalin and Calreticulin are measurable in muscle biopsies from human SMA patients. (A) Representative fluorescent
western blots on quadriceps femoris muscle biopsy samples from an SMA patient (type II/III) and an age-matched non-SMA control showing levels
of GRP75/Mortalin, Calreticulin and Ponceau (loading control). (B,C) Bar charts showing expression levels of GRP75 and Calreticulin in human SMA
patient muscle biopsies compared with controls. Data are shown for each individual patient (black and white bars to the left of the dashed line;
error bars show variability between two independent measurements taken from that individual’s biopsy), as well as pooled mean for each patient
group (right of the line; ± standard error of the mean; n = 6 measurements for each group, two independent measurements from each patient
biopsy). (B) GRP75 levels showed a trend towards increased expression in SMA patients, but this difference did not reach statistical significance
(ns, not significant; P > 0.05, unpaired, two-tailed t-test). (C) Calreticulin levels were significantly increased in SMA patient muscle (*P < 0.05, unpaired,
two-tailed t-test).
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(Figure 3C); however, there was still considerable variability
between individuals. Whilst these experiments only repre-
sent an initial attempt to measure GRP75/Mortalin and
Calreticulin levels in human patient muscle biopsies, and
are limited by the very small sample size, our preliminary
investigations suggest that both Calreticulin and GRP75/
Mortalin may represent accessible protein biomarkers
in skeletal muscle conserved between mouse models and
human patients.
Altered levels of GRP75/Mortalin and Calreticulin can be
detected in skin biopsies from SMA mice
Our analyses of GRP75/Mortalin and Calreticulin levels
in skeletal muscle from SMA mouse models (supported
by preliminary investigations of human patient tissue)
suggested that these two proteins may represent robust
protein biomarkers for SMA. However, obtaining muscle
biopsies from human patients is an invasive procedure
that is not ideal for repeated analyses of protein levels
during a clinical trial, especially in small children. As a
result, the availability of biomarker proteins in more
peripherally accessible tissue (such as skin and/or blood)would make it much easier to obtain quick, repeated tissue
samples for monitoring purposes. Therefore, we next asked
whether GRP75/Mortalin and Calreticulin protein could be
reliably identified and measured in skin and blood. Analysis
of expression datasets [34] confirmed that both GRP75/
Mortalin and Calreticulin are known to be expressed in
skin and whole blood. To establish whether these proteins
were detectable in skin and blood samples from our mouse
models we performed standard quantitative fluorescent
western blotting for both of these proteins on samples
taken from ‘Taiwanese’ SMA mice and littermate controls
at P9. Neither GRP75/Mortalin nor Calreticulin could
be reliably detected in whole blood (data not shown).
However, both proteins were robustly expressed in skin
samples, with their levels being significantly increased in
SMA mice compared to controls (Figure 4). Thus, both
GRP75/Mortalin and Calreticulin were readily identifiable
in skin biopsies, with the alterations in their levels in skin
closely matching alterations previously observed in skeletal
muscle (Figure 4B,D).
Finally, we wanted to establish whether GRP75/Mortalin
and Calreticulin levels in skin matched the temporal
profile we originally identified in our muscle proteomics
Figure 4 Increased levels of Calreticulin and GRP75/Mortalin in skin biopsies correlate with disease progression in SMA mice.
(A) Representative fluorescent western blots on skin tissue from ‘Taiwanese’ SMA mice and littermate controls at P9 (mid/late-symptomatic)
showing levels of GRP75/Mortalin, Calreticulin and Ponceau (loading control). (B,D) Bar charts (mean ± standard error of the mean) showing
expression levels of GRP75/mortalin and Calreticulin in ‘Taiwanese’ SMA mice (knockout (KO)) and controls at P9 (N = 3 mice per genotype).
(B) GRP75/Mortalin levels were significantly increased in ‘Taiwanese’ SMA mice compared with controls (***P < 0.01, unpaired, two-tailed t-test).
(D) Calreticulin levels were significantly increased in Taiwanese SMA mice compared with controls (**P < 0.01, unpaired, two-tailed t-test).
(C,E) Time course of GRP75/Mortalin and Calreticulin expression in skin biopsies from ‘Taiwanese’ SMA mice (KO) compared to controls (Het)
(N = 3 mice per genotype/time-point). Tissue was analysed in mice at P1, P5 (both pre/early-symptomatic), P7 (early-symptomatic) and P9
(mid/late-symptomatic). (C) There was no increase in GRP75/Mortalin levels in Taiwanese SMA mice until after overt disease onset. (E) Similarly,
there was no increase in Calreticulin levels in Taiwanese SMA mice until after overt disease onset.
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‘Taiwanese’ SMA mice and littermate controls at four
different time-points: P1 and P5 (pre-symptomatic), P7
(early-symptomatic), and P9 (mid/late-symptomatic).
Temporal changes in the levels of GRP75/Mortalin and
Calreticulin showed similar trends in SMA mouse skin,with no differences observed at pre/early-symptomatic
time-points, but robust increases evident after onset of
symptoms at P6 (Figure 4C,E). Thus, the temporal ex-
pression of GRP75/Mortalin and Calreticulin revealed a
very similar profile in skin to that previously observed
in skeletal muscle. Once again, the robust increases in
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that GRP75/Mortalin and Calreticulin represent peripher-
ally accessible protein biomarkers capable of reporting on
disease status in SMA.
Discussion
In this study we used label-free proteomic technology to
identify two proteins with the potential to act as molecular
biomarkers for SMA. The combination of proteomics
technology with an established mouse model of SMA
(where it is possible to accurately identify and isolate
tissue from animals at different stages of disease) revealed
that increased levels of GRP75/Mortalin and Calreticulin
in skeletal muscle correlated with disease progression.
Importantly, these protein biomarkers were also accessible
in skin samples from SMA mice, suggesting that they can
also be monitored in a peripherally accessible tissue during
clinical trials. A preliminary study on a small sample of
patient muscle biopsies suggested that GRP75/Mortalin
and Calreticulin were detectable and measurable in human
tissue, including biopsies from SMA patients.
The use of label-free proteomics in this study provides
further evidence that proteomics technologies represent a
powerful tool for biomarker discovery [20]. Indeed, prote-
omics technology has previously been used to screen
for potential biomarkers in human SMA patients [19,21].
Previous studies combining proteomics with animal
models of SMA have mainly utilized the technology to
uncover molecular pathways disrupted downstream of
SMN [7,30,35,36], but the current study demonstrates
that similar approaches can be used to identify potential
protein biomarkers for future use in the human clinical
context. In addition, our ability to identify protein bio-
markers conserved between different mouse models of
SMA and human SMA patients suggests that common
biomarkers can be utilized in both pre-clinical testing of
new treatments in animal models as well as in human
clinical trials. It should be noted that our proteomics study
identified approximately 500 muscle proteins, which is
predicted to represent only a fraction of the total muscle
proteome. Thus, there are likely to be other proteins in
SMA skeletal muscle yet to be identified that have the
potential to act as novel biomarkers for the disease
alongside GRP75/Mortalin and Calreticulin.
Calreticulin is a multifunctional protein that has pre-
viously been identified as a potential biomarker for
other diseases. For example, serum levels of Calreticulin
have been shown to increase in patients with rheumatoid
arthritis [37] and increased levels of Calreticulin have been
reported in breast cancer [38,39], gastric cancer [40], and
lung cancer [41]. Calreticulin has also been identified as
a prognostic factor for neuroblastoma [42]. However,
Calreticulin has not previously been linked to SMA, and
whether it is actively involved in disease pathogenesis ornot remains unclear. Interestingly, Calreticulin has been
implicated in regulating motor neuron pathology in a
related motor neuron disease (amyotrophic lateral sclerosis;
ALS) [43], suggesting that, alongside its potential to act as
a molecular biomarker for SMA, further investigations
into its possible contribution to the pathogenesis of SMA
are warranted.
GRP75/Mortalin is a member of the Hsp70 family of
chaperones, with roles including the regulation of energy
generation, stress responses, muscle activity, mitochon-
drial activity, and cellular viability [44-46]. As with Calreti-
culin, GRP75/Mortalin has previously been identified as a
possible biomarker for cancer and cardiovascular diseases
[47] as well as being a potential prognostic factor for
neuroblastoma [48]. GRP75/Mortalin (also known as
HSPA9) has also been implicated in the pathogenesis of
other neurodegenerative conditions, including Parkinson’s
disease [49] and Alzheimer’s disease [50], suggesting that
it, too, may be contributing directly to SMA pathogenesis.
Nevertheless, it is important to note that biomarkers do
not need to actively contribute to disease pathogenesis in
order to be effective. What is critical is that the levels
of a biomarker must alter in a temporally traceable and
predictable manner as an accurate measure of the molecu-
lar and physiological processes of disease progression. Both
GRP75/Mortalin and Calreticulin appear to meet these
criteria in SMA.
Our preliminary investigation of GRP75/Mortalin and
Calreticulin levels in human skeletal muscle suggests that
these proteins may represent viable biomarkers in human
SMA patients. However, it represents only an initial
demonstration of the ability to detect and measure these
proteins in human tissue, and was hampered by a lack of
detailed information from the biobank regarding the
actual stage of disease progression for each patient at
the time of muscle biopsy, as well as the small sample
size. As a result, further, large-scale studies on patient
cohorts will now be required to validate GRP75/Mortalin
and Calreticulin as robust protein biomarkers for SMA
in humans. The demonstration in mouse models that
increased levels of these proteins correlated with increasing
disease severity suggests that such a study is now
warranted. Moreover, the finding that these proteins
can be tracked in skin samples suggests that the use of
skin biopsies might be of more practical use for these
studies, reducing the need for repeated invasive muscle
biopsies.
Conclusions
We conclude that label-free proteomics technology
provides a powerful platform for biomarker identification
in SMA. Combining label-free proteomics with established
mouse models of SMA led to the identification of Calreti-
culin and GRP75/Mortalin as protein biomarkers capable
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http://genomemedicine.com/content/5/10/95of reporting on disease progression in tissue samples of
muscle and skin. When used alongside the genetic SMN
status of SMA patients, these biomarkers should provide
an additional means through which the disease can be
monitored and tracked. Further work is now warranted
to validate these protein biomarkers in cohorts of SMA
patients.
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